The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy.


Journal

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
ISSN: 1899-1505
Titre abrégé: J Physiol Pharmacol
Pays: Poland
ID NLM: 9114501

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 02 11 2021
accepted: 28 02 2022
entrez: 31 5 2022
pubmed: 1 6 2022
medline: 3 6 2022
Statut: ppublish

Résumé

This study aimed to observe the efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy (DN) and investigate its effect in reducing urinary protein levels. A total of 132 patients with DN and normal renal function (estimated glomerular filtration rate >60 ml/min/1.73 m

Identifiants

pubmed: 35639038
doi: 10.26402/jpp.2022.1.06
doi:

Substances chimiques

Canagliflozin 0SAC974Z85
Irbesartan J0E2756Z7N

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Auteurs

F P Zhang (FP)

Department of Endocrinology, Tianjin First Center Hospital, Tainjin, China.

X Jiang (X)

Department of Endocrinology, Tianjin First Center Hospital, Tainjin, China. endojiang621@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH